WHO FCTC Announces Opening of COP10

2Firsts Events by 2FIRSTS.ai
Feb.06.2024
WHO FCTC Announces Opening of COP10
The World Health Organization Framework Convention on Tobacco Control (WHO FCTC) announces the opening of its 10th Conference of Parties (COP10).

The 10th Conference of the Parties (COP10) of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was officially announced on the organization's website on February 5th.

 

The 183 signatories of this convention, representing over 90% of the global population, are collectively working to strengthen and promote tobacco control. Despite the ongoing global population growth in the first two decades of this century, the smoking rate among adults has dropped from nearly 33% to 22%.

 

Dr. Adriana Blanco Marquizo, Director of the Secretariat of the WHO Framework Convention on Tobacco Control, welcomed the participants and raised concerns about the growing prevalence of emerging nicotine and tobacco products.

 

She pointed out that these products "have become a concerning issue, with young people rapidly increasing their usage. One of the reasons is the tobacco industry's misleading information, portraying these products as substitutes for real tobacco control measures. The tobacco industry is once again trying to gain a foothold in addressing the epidemic problem it created and continues to perpetuate.

 

She further urged everyone to be vigilant about the relentless interference of the tobacco industry worldwide, highlighting that "the tobacco industry is attempting to undermine not just COP10, but the efforts of every Conference of the Parties.

 

The Conference of the Parties (COP) is the decision-making body of the World Health Organization Framework Convention on Tobacco Control, comprising of all the treaty's signatories. It regularly reviews the implementation of the convention and makes necessary decisions to promote its effective implementation.

 

The conference will consider a range of actions to guide future work on addressing the global tobacco epidemic, which annually claims the lives of 8.7 million people worldwide, in line with the World Health Organization's Framework Convention on Tobacco Control.

 

The discussion topics at COP10 include:

 

  • Implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control (Regulation of Tobacco Product Ingredients and Disclosure): Report Presented by the Bureau, Expert Group, and WHO  
  • Tobacco Advertising, Promotion, and Sponsorship: Depictions of Tobacco in Entertainment Media: Report Presented by the Working Group  
  • NTPs and Emerging Tobacco Products  
  • Future Tobacco Control Measures (Related to Article 2.1 of the WHO Framework Convention on Tobacco Control)  
  • Implementation of Article 19 of the WHO Framework Convention on Tobacco Control: Responsibilities  
  • Improving the Reporting System of the WHO Framework Convention on Tobacco Control  
  • Implementation Review Mechanism  
  • Contribution of the WHO Framework Convention on Tobacco Control to the Promotion and Realization of Human Rights  
  • WHO Framework Convention on Tobacco Control Investment Fund

Furthermore, discussions on the tobacco control investment fund and the upcoming COP10, scheduled to run from today until Saturday, February 10th, are expected. Following that, the Third Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products (MOP3) is set to take place from Monday, February 12th, to Thursday, February 15th, 2024.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08